On the date of publication, William Whitedid not have (either directly or indirectly) any positions in the securities mentioned in this article. Global financial customers and partners gathered to discuss the acceleration of technology application and innovative improvement of productivity. Learn More. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. Additional information concerning these and other risks can be found in Progenitys periodic filings with the SEC, including under the heading Risk Factors contained therein. If Pfizer wants to fill its pipeline with precision-medicine oncology drugs for the next decade, perhaps it will consider Blueprint Medicines (BPMC 4.57%). 10 Its key products . In the U.S. alone, an estimated 147,950 people will be diagnosed with cancer of the colon or rectum in 2020, and approximately 53,000 are estimated to die of their disease each year. The deal cost Pfizer $650 million upfront, as well as a $350 million equity investment and up to $1.4 billion in milestone payments. Read More: Penny Stocks How to Profit Without Getting Scammed. DATE SIGNED Return this form to: Federal Trade Commission Room H-113 600 Pennsylvania Avenue, N.W. ASSOCIATE/ASSISTANT DIRECTOR 4. Shares of Progenity ( PROG -8.76%) were up more than 24% on Friday. PROG got a patent for its Preecludia test. Progenitys mission certainly sounds good on paper, and its more than just fantastical what one day will be kind of stuff too. on March 8th, 1pm MST, for a no-BS, female founder-led, 'behind the curtain' conversation on IG Live @NULASTIN. Meanwhile, there are strong signs that both OBDS and Preecludia work well. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Discover something new every day from News, Sports, Finance, Entertainment and more! Among his highlysuccessful, contrarian picks have been Plug Power, solar stocks, and Snap. First Solar rose on earnings. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund. Progenity (NASDAQ:PROG) is developing two products that look poised to become quite lucrative. Pfizer has paid Beam. If you have an ad-blocker enabled you may be blocked from proceeding. Our 7 Top Picks. While its legacy business is ending, the company now plans to become a clinical-stage biotech company. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sign up below to get this incredible offer! Valorisation Recherche Hscm, Limited Partnership: . Our Research & Development colleagues are working at sites across the globe to support our product pipeline. Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA (adalimumab-afzb), as a biosimilar to Humira (adalimumab), 1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's Lung cancer remains the leading cause of cancer-related death among men and women globally, and the global five-year survival rate at 17.8 percent is much lower than leading cancers. Chris Tyler is a former floor-based, derivatives market maker on the American and Pacific exchanges. Article printed from InvestorPlace Media, https://investorplace.com/2021/11/say-goodbye-not-good-buy-to-the-progenity-short-squeeze/. Two Wall Street Legends will reveal their #1 recommendations and full "roadmap" for navigating the coming AI revolution. Still, the Mayo Clinic reports that many tests, such as blood tests, fetal ultrasound and a nonstress test or biophysical profile currently may be needed to determine if a woman has Preeclampsia. And despite impressive COVID-19 data from Atea, Pfizer has its own oral coronavirus treatment early in progress, though not quite as far along in clinical trials. In some cases, you can identify forward-looking statements by terms such as may, might, will, objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential, develop, plan or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. The stock, which closed at $3.13 on Tuesday, opened at $3.21 today, but . On the other hand, if they miss, the stock may move lower. Given these points, Progenity appears set to report very strong financial results in several years. Ecora Resources PLC (LSE:ECOR)(TSX:ECOR) announces that on 27 February 2023 the Company transferred 47,244 ordinary shares of 2 pence each in the Company ("Ordinary Shares") out of treasury (the "Transfer"), to satisfy awards vesting under the Company's Deferred Share Bonus Plan for a number of employees, including Mr. Kevin Flynn, Chief Financial Officer of the Company. Nasdaq We look for treatments that provide more than just symptom relief,in orderto address the root cause of chronic inflammatory diseases at a molecular level. At least 22 people, including children, were abducted from three villages in northern Congo, local authorities said. To read this article on Zacks.com click here. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Speaking back in May on his company's Q1 2021 earnings call, Pfizer (PFE -0.52%) CEO Albert Bourla stated, "You should expect to see a lot of business development deals that will allow us to bring in-house a lot of potential medicines that could become [approved treatments] in the second part of the decade." Not necessarily it could be earlier just depends on the data coming out. 1125 N. Charles St, Baltimore, MD 21201. The study was small, but it's some of the first data we have on vaccines and male fertility. With a market cap of less than $2 billion and a potential blockbuster that has possible optionality into other autoimmune diseases, Aurinia looks undervalued and could find itself being acquired sooner rather than later. Revenues are expected to be $11.1 million, down 57.2% from the year-ago quarter. ', UK mortgage approvals slump for fifth straight month as higher rates hit buyers, Relatives pay respects as toll from Italy migrant boat wreck rises to 67, Stars including Charlize Theron and Gal Gadot arrive for Dior show in Paris, UPDATE 1-China scoffs at FBI claim that Wuhan lab leak likely caused COVID pandemic, ESPNs Mel Kiper Jr. switches pick to Bills offense in latest 2023 mock, With few objections, MLB's new pitch clock is already having its intended effect, GREAT GULF GROUP APPOINTS KIEL O'SULLIVAN PRESIDENT US SINGLE-FAMILY BUILD-TO-RENT, My 10 Best Dividend Stocks to Buy Now in March, Ecora Resources PLC Announces Notification of transactions by Directors, Bright Health Group Reports Fourth Quarter and Full Year 2022 Results, Huawei: Accelerate Change, Shaping Smarter Greener Finance Together, Stewart Enhances Credit and Mortgage Analytics Capabilities by Acquiring AccountChek, a Leading Digital Asset, Income and Employment Verification Platform, Vista Gold Corp. Reports Encouraging Potential for Smaller-Scale Development Plan at Mt Todd, 1 Exceptional ETF to Buy During a Recession. And, needless to say, the odds of any early stage drug actually making it through Phase 3 trials and getting Food and Drug Administration (FDA) approval is quite low. The Pfizer-BioNTech vaccine requires two injections, given 21 days apart, to prime the immune system well enough to fight off the coronavirus. Copyright Progenity suggested that products such as its prenatal genetics tests could improve peoples lives. And while its nice to dream about another successful short squeeze campaign like Januarys GameStop (NYSE:GME) squeeze, which put Reddit on Wall Streets radar, most schemes of that nature fail. Say Goodbye Not Good Buy to the Progenity Short Squeeze, 5 Hypergrowth Stocks With 10X Potential in 2023, How to Tell if an AI Company Is Legit or Selling Snake Oil, Expect the Amazon Stock Slump to Continue, Louis Navellier and the InvestorPlace Research Staff. What Is the Best Tech Stock to Buy Now? PROG stock was up 14.7% as of Tuesday afternoon. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. With pre-tax profit on its COVID-19 vaccine in the high 20% range and Bourla's company guiding for $78 billion to $80 billion in revenue for 2021 (with more than $33 billion of that coming from the vaccine), there's certainly money to be spent on acquisitions. Spring training's early returns show that baseball's new pitch clock is successfully shortening games. Historically, PROG stock has been a disappointment. Even better, this doesn't even get into the potential for Lupkynis to treat other autoimmune diseases. The business owners that power this multibillion dollar industry are changing, and a new era of the business of sports is underway. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Progenity, Inc. (PROG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. 3. The aggregate purchase price of each unit, which consists of one share of common stock (or pre-funded warrants in lieu thereof) plus a warrant to purchase one share of common stock, is $2.47. Merely a month later, PROG stock lost half its value on this news. In fact, 40.8% of patients see improvements in renal function after 52 treatments with Lupkynis, versus 22.5% receiving standard-of-care treatment alone. Over the last four quarters, the company has beaten consensus EPS estimates two times. Shares lost the majority of their value within days of that deal closing. Further, the reality is the staying power of apes mostly responsible for Progenitys swing higher is typically unreliable and of the one-trick pony variety. And while PROG stock is a name youre likely to have not crossed paths with, a nearly nine-fold increase in volume totaling more than 3 billion shares indicates others certainly have, and for good reason. The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. A new brochure, 'IMI - radical collaboration in action', showcases some recent IMI project successes, which include an approved vaccine for Ebola, insights into the genetics of Alzheimer's disease, a new classification of diabetes, and advances on using liquid biopsies for cancer, as well as contributions to the fight against COVID-19. Remember the merger that was Support.com with bitcoin mining firm, Greenidge Generation Holdings(NASDAQ:GREE)? A financial industry forum titled "Accelerate Change, Shaping Smarter Greener Finance Together" is successfully held during the 2023 Mobile World Congress (MWC 2023). Lupus nephritis is an autoimmune disorder that's especially harsh on the kidneys, with approximately 10% to 30% of patients experiencing kidney failure within 15 years, despite current therapies. Fortunately, there's one investment that can help protect your savings: an S&P 500 ETF. Progenity, Inc. (PROG) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ETCompany ParticipantsRobert Uhl - Managing Director, Westwicke ICRDr. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. 1125 N. Charles St, Baltimore, MD 21201. Your trust is our top concern, so companies can't alter or remove reviews. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. The precision-medicine company also has two candidates entering phase 1 studies for non-small cell lung cancer with mutations within a specific gene called EGFR. Progenity intends to use the net proceeds to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform, and for working capital and general corporate purposes. And Pfizer also lifted its forecast for total revenue to at least $81 billion. Copyright 2023 InvestorPlace Media, LLC. You can reach him on Twitter at @irbezek. Progenity ( PROG -0.85%), a biotech company and a meme stock favorite, saw its shares decline more than 11% on Wednesday. Powered by Nasdaq Data Link. That makes some sense from a financial perspective, but it doesnt give much in the way of near-term catalysts to boost PROG stock. Please disable your ad-blocker and refresh. ) For additional market insights and related musings, follow Chris on Twitter @Options_CATandStockTwits. All statements, other than statements of historical facts included in this press release, including, but not limited to, Progenitys expectations regarding the completion of the private placement, the satisfaction of customary closing conditions related to the private placement and the expected receipt of proceeds from the private placement, are forward-looking statements. GU cancers are pervasive and notoriously hard to treat, despite available therapies. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. Nasdaq Anti-infectivesAntimicrobial ResistanceAMR PreventionAntimicrobial SurveillanceAntimicrobial StewardshipOur Commitment as a Global LeaderEnvironmental Protection, Senior Vice President & Chief Scientific Officer, Rare Disease, Associate Research Fellow and Group Leader, Chemical Development Active Pharmaceutical Ingredients, Executive Director, Patient Advocacy Lead, Vice President, Clinical Portfolio Leader, I&I Research Unit, Senior Director, Biology and Nice Site Lead, Vice President and Clinical Portfolio Leader, Senior Vice President of Pfizer Vaccine Clinical Research and Development, Chief Medical Officer and Head of Worldwide Medical & Safety, SVP & Chief Medical Officer, Pfizer Vaccines, Senior Director, Oncology Medicinal Chemistry Synthesis and Analytical Group, Vice President, Head of Scientific Research, Principal Scientist, Oncology Medicinal Chemistry, Vice President, Gene Therapy and Discovery Biology, Vice President, Rare Neurology and Discovery Biology, Senior Vice President and Chief Scientific Officer, Internal Medicine Research Unit, Senior Research Fellow, Pharmaceutical Sciences, Sr. Progenity is also developing a test for preeclampsia, called Preecludia. Yup, similar, but FAR FAR easier/ simplistic. " Bad upper management, rude and unprofessional." (in 8 reviews) "Systemically rotten to the core with management running the culture into the ground." $7.06 * 10. Shares have started to slide again. Bottom-line though, if readers see things differently, agreeably please look to hedge whats a much riskier risk-asset with a longer-term bull call spread, stock collar or married put strategy. Progenity (NASDAQ:PROG) is a biotech firm focused on treatments and testing products for a variety of diseases. Progenity's Oral Biotherapeutic Delivery System is an ingestible capsule that can be swallowed to deliver large molecules, including monoclonal antibodies, peptides, and nucleic acids, rather than via injection. Any forward-looking statements that Progenity makes in this press release speak only as of the date of this press release. As the company points out in its investor presentation, direct and noninvasive access to. Bill Tresham, Executive Chairman Great Gulf Group, is pleased to announce the appointment of Kiel O'Sullivan as President of Granden Living the Group's US single-family build-to-rent business. It has said it will . Article printed from InvestorPlace Media, https://investorplace.com/2021/12/prog-stock-looks-poised-to-become-a-big-winner/. It all happens at the free AI Super Summit. Investor Contact:Robert UhlManaging Director, Westwicke ICRir@progenity.com (619) 228-5886, Media Contact:Kate Blom-LoweryCG Lifemedia@progenity.com (619-743-6294). The real work is coming! Find the latest Biora Therapeutics, Inc. (4ZU.F) stock discussion in Yahoo Finance's forum. Passive income investors can also reasonably expect these companies to steadily increase their dividend payments in future years. Today, PROG stock has moved more than 15% higher at the time of writing on very heavy volume. As a result of earlier screening, increased awareness, and better treatments, breast cancer deaths have continued to decrease in older women. 2023 InvestorPlace Media, LLC. We are pleased the USPTO has granted this patent covering unique and novel methods for determining levels of free and dissociated PlGF, since detection and quantification of both biomarkers are critical for assessing preeclampsia. And a deeper look into the company explains the weakness. Yet at this point, biologics, including monoclonal antibodies, can only be administered intravenously. Sorry, you need to enable JavaScript to visit this website. With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. On the other hand, the stock currently carries a Zacks Rank of #3. You can reach him on StockTwitsat@larryramer. News of the study comes after the U.S. Centers for Disease Control and Prevention (CDC) announced on May 17 that its Advisory Committee on Immunization Practices (ACIP) was investigating several. Larry began writing columns for, in 2015. SIGNATURE OF SENIOR COUNSEL 5. These are small test runs in healthy patients to see whether a basic idea works or not. Rescuers said most of the migrants came from Afghanistan, with others from Pakistan, Iran, Somalia and Syria. The latest Bank of England figures show sharp declines in mortgage approvals and lending in January. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. "The FBI has for quite some time now assessed that the origins of the pandemic are most likely a potential lab incident in Wuhan," Wray told Fox News. Progenitys OBDS looks poised to become very valuable for healthcare providers, drug makers and patients. On the OBDS front, Progenity is already partnering with three drug makers, including at least one major pharmaceutical company, with which it established an alliance in the third quarter. The Motley Fool has a disclosure policy. You can reach him on, 5 Hypergrowth Stocks With 10X Potential in 2023, How to Tell if an AI Company Is Legit or Selling Snake Oil, Expect the Amazon Stock Slump to Continue, Louis Navellier and the InvestorPlace Research Staff. Pfizer will pay Beam $300 million to develop treatments for rare genetic diseases of the liver, muscle and central nervous system as part of the four-year deal, rising by more than $1 billion . KB: None to declare. Two Wall Street Legends will reveal their #1 recommendations and full "roadmap" for navigating the coming AI revolution. Thats all well and good, but its the first step of a great many in going anywhere in clinical drug development. Progenity claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. 4. And we haven't even mentioned Blueprint's other approved drug, which is for a rare disease called mastocytosisand has an addressable market in the U.S. of at least $800 million. Explore all of our disease and condition-related resources to learn more about your diagnosis and treatment options. Copyright 2023 InvestorPlace Media, LLC. Now that they have their last resistance, we can start with the real work from today! And then things went from bad to worse. Atea partnered with Roche in October 2020 on AT-527, and the drug is now in an ongoing worldwide phase 3 trial with results due in the second half of 2021. Investor Contact:Robert UhlManaging Director, Westwicke ICRir@progenity.com (619) 228-5886, Media Contact:Kate Blom-LoweryCG Lifemedia@progenity.com (619) 742-6294. Principal Scientist, Biotherapeutics Pharmaceutical Sciences, Associate Research Fellow, Hit Discovery and Lead Profiling. Tinyman let's you swap ALGO for Yieldly, which you can then stake on yieldly for both yieldly and ALGO rewards (roughly 40% APY). It all happens at the free AI Super Summit. Yet those performances paled to small-cap, biotech play Progenity, which saw its shares soared nearly 137%. JKM: Is an employee of Alimentiv Inc. GGK: Honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, Amgen, Sandoz, Pendophram, and Takeda. With COVID-19 cases rising worldwide, there's a pressing need for an efficacious oral therapy that can be administered not only to hospitalized patients but also to those well enough to be given a prescription as outpatients. AccountChek is a digital verification of asset, income and employment service that drives insight into a consumers financial profile and is available to customers through multiple channels. 5 Hypergrowth Stocks With 10X Potential in 2023, assessment of preeclampsia using assays for free and dissociated placental growth factor., LCID Stock: Why Lucid Shares Are Going in Reverse on Tuesday, Casino Stocks: Why WYNN, LVS, MLCO and MGM Are Taking a Hit Today, LIFE Stock: 7 Things to Know About Biotech aTyr Pharma as Shares Soar on Study Results, How to Tell if an AI Company Is Legit or Selling Snake Oil, Expect the Amazon Stock Slump to Continue, Louis Navellier and the InvestorPlace Research Staff. Progenity completed its IPO in June 2020. Polygon MATIC price surpasses $1.50 for the first time since April 2022. Our Centers for Therapeutic Innovation collaborates with academic institutions and investigators to push forward great science, using the depth and breadth of the Pfizer enterprise to accelerate concepts into viable therapies with breakthrough potential for patients. A pre-print study in Israel found no change in sperm of men who got Pfizer's COVID-19 vaccine. Real Women. The National Bureau of Economic Research is responsible for making that call, and economists will look at a variety of factors -- such as the unemployment rate, consumer spending, and GDP -- to determine when a recession begins. The stock might move higher if these key numbers top expectations in the upcoming earnings report. But with revenues plunging and the DoJ news adding more headwinds, Progenity wound down the testing business. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. EmotionalAd1939 1 yr. ago. Copyright The company expects it to reach a $3 billion a year market in the U.S. That includes the laboratory-developed test immunodiagnostic thats under development. Sign up below to get this incredible offer! While Gavreto competes with Eli Lilly'sRetevmo in this market, the Roche-Blueprint product currently has a 40% share of the RET-inhibitor space, despite being the second one to the party. Pharma Atea Pharmaceuticals (AVIR -0.56%)reported interim phase 2 results at the end of June showing that its lead COVID-19 oral treatment, AT-527, could rapidly reduce the viral load in COVID-19 patients. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. See inside for details on which companies are reducing staff to increase cash flow. All rights reserved. Ian Bezek has written more than 1,000 articles for InvestorPlace.com and Seeking Alpha. Housing Market Crash Alert: Mark Your Calendars for Feb. 28, Adopt the AI Revolution Before It Crowns the Next-Generation of Billionaires. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Whats more, the market capitalization of PROG stock, which is around $385 million, is quite reasonable in light of the companys tremendous potential. MINNEAPOLIS, March 01, 2023--Bright Health Group reports Q4 and full-year results for 2022. Pfizer has several key areas of interest where we are looking to partner with others. Progenity's products are very promising, making PROG stock attractive. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. 16. However, theres no fundamentals to support the share price, so be most wary with any moves in PROG stock. Progenity, Inc. Appears a compelling earnings-beat candidate. Most schemes arent GME stock or an AMC Entertainment (NYSE:AMC). Copyright Hopefully sooner, but yeah most likely in the mid/late clinical trial stage once enough data has been collected for FDA approval. All told, I strongly suspect bears arent going to miss this opportunity, as well as the one on the price chart featuring a tenuous higher-low pattern and ominous stochastics setup. 2023 InvestorPlace Media, LLC. Pfizer Inc: Pharmaceutical combination US6790856B2 (en) * 2002-01-31: 2004-09-14 . On the date of publication, Larry Ramer did not have (either directly or indirectly) any positions in the securities mentioned in this article. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. 1125 N. Charles St, Baltimore, MD 21201. Progenity says that its planning for commercialization opportunities to launch the laboratory-developed test in the U.S. Its also searching out ways to commercialize the in vitro diagnostic test across the globe. Progenity, Inc. Larry began writing columns forInvestorPlace in 2015. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement. Nasdaq If you think youre a buyer of PROG stock, holding off looks like a very good idea in our estimation. An Atea buyout also would provide a safety net should Pfizer's own oral combination therapy for COVID, which just entered phase 2/3 trials, fizzle out. swriters disclose this fact and warn readers of the risks. While we're looking at data, it should be noted that. That includes why Lucid Motors(NASDAQ:LCID) stock is falling, what has casino stocks down, as well as the cause behind Atyr Pharma(NASDAQ:LIFE) soaring higher. When Aurinia Pharmaceuticals' (AUPH 9.12%) Lupkynis was approved in January, it became the first oral therapy approved for lupus nephritis that doesn't require monitoring of drug levels. Real Women. Wall Street expects a year-over-year increase in earnings on lower revenues when Progenity, Inc. (PROG) reports results for the quarter ended September 2021. At the time of writing, nearly three times the average daily number of shares have been traded . Matthew Cooper, PhD, chief scientific officer of Progenity, said this about the news boosting PROG stock up today. That makes the biotech one of the markets most-heavily wagered against in terms of float. Copyright 2023 InvestorPlace Media, LLC. UTI Limited Partnership, assignee. Buy buy buy and HODL. Thousands of users reported problems starting around 5:15 a.m. Copyright 2023 InvestorPlace Media, LLC. Actual results may differ materially from these forward-looking statements. The patent for Progenity is for its assessment of preeclampsia using assays for free and dissociated placental growth factor. This covers methods, compositions, and kits that can detect and measure free and dissociated placental growth factor levels in biological samples. As mentioned, Progenitys results slumped in 2020. This was a rather remarkable turn of events for a company that IPOed just one year ago on the strength of this now-shuttered business. The ideal candidate may already have drugs on the market that could benefit from Pfizer's marketing team. SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11 th annual. quotes delayed at least 15 minutes, all others at least 20 minutes. 2023 InvestorPlace Media, LLC. These statements involve known and unknown risks, uncertainties and other factors that could cause Progenitys actual results to differ materially from the forward-looking statements expressed or implied in this press release, the uncertainties related to market conditions and the completion of the offerings on the anticipated terms or at all, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process, the timing of regulatory filings, and other matters, including the ongoing COVID-19 pandemic, that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of Progenitys products, and those risks described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in Progenitys Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q.
Who Is Exempt From Paying Property Taxes In Florida,
Oklahoma Property Fence Laws,
Trey Lance Throwing Motion,
Shanti Lowry Related To Tia And Tamera,
Articles P